Clinigen Group plc: Underlying EBITDA up 19.8% and EPS up 22%
Business Wire - Wed Sep 24, 1:10AM CDT
Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2014.
New Antibiotic VIBATIV(R)a- 1/4 (telavancin) Targets Public Health Priority MRSA Infections for People with Hospital-Acquired Pneumonia Across Europe
PR Newswire Europe - Thu Sep 18, 7:42AM CDT
BURTON-ON-TRENT, England, September 18, 2014 /PRNewswire/ --
Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol(R) (amifostine), from AstraZeneca
Business Wire - Wed Aug 20, 1:07AM CDT
Clinigen Group plc ('Clinigen' or the 'Group'
Clinigen Group Acquires Oncology Support Therapy SAVENE(R) (dexrazoxane) from SpePharm AG
Business Wire - Mon Mar 31, 1:00AM CDT
Clinigen Group plc ('Clinigen' or the 'Group'
Clinigen Group plc: Half Year Results for the Six Months Ended 31 December 2013
Business Wire - Wed Feb 26, 1:18AM CST
Clinigen Group plc (AIM: CLIN, Clinigen or the Group), the global specialty pharmaceuticals and pharmaceutical services business, has today published its half year results for the six months ended 31 December 2013.